Caractéristiques cliniques des patients présentant une poussée de sclérose en plaques sans modification de signal à l'IRM

Summarise with VIRAT
Authors: Perle Brugidou
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Introduction: recent studies have reported that acute clinical events with stable magnetic resonance imaging (MRI) acute clinical event with stable MRI (ACES) occur in patients with multiple sclerosis (MS), particularly in those treated with anti CD20 therapies or Natalizumab. These relapses, which lack corresponding radiological activity, remain insufficiently studied. AIM: to identify factors associated with relapses without new MRI lesions (ACES) in comparison to relapses with active MRI (RAM). Method: MS relapses were identified from the french multiple sclerosis observatory (OFSEP) database at Bordeaux university hospital, including patients who had received at least one injection of an anti CD20 therapy or Natalizumab since 2008. Each relapse was manually reviewed in the clinical files and categorized as either ACES or RAM. Data collected included the presence of new neurological location on clinical examination, treatment type, expanded disability status scale (EDSS) score, and other clinical variables. Multivariate logistic regression was used to determine factors associated with ACES. Results: among 4,704 clinical events reviewed, 760 relapses were included : 377 were classified as ACES and 383 as RAM. The proportion of patients receiving high-efficacy monoclonal antibody therapies (HET) was significantly higher among ACES cases (36.3%) than among RAM cases (9.7%), p < 0.001. ACES cases involved a new neurological territory less frequently (34.0%) than RAM cases (61.4%), p < 0.001. Patients with ACES had a longer mean disease duration (9.7 years vs. 8.3 years for RAM, p < 0.001) and a higher mean EDSS score before relapse (2.8 vs. 2.2, p < 0.001). In multivariate analysis, ACES were significantly associated with HET (OR 4.11; 95% CI [2.35–7.17], p < 0.001), absence of new neurological location (OR 1.88; 95% CI [1.24–2.85], p = 0.003) and higher EDSS score prior to relapse (per 1-point increase: OR 1.19; 95% CI [1.03–1.38], p = 0.022). Conclusion: relapses without new MRI lesions (ACES) are significantly more likely in patients treated with high efficacy therapies, with no new neurological territory affected, and higher baseline disability. These findings suggest that ACES represent a distinct clinical phenotype that warrants specific diagnostic and therapeutic considerations.

Fields of Study & Subjects

Multiple Sclerosis Research Studies Polyomavirus and related diseases Peripheral Neuropathies and Disorders

Publication details

Journal / source
HAL
Publication date
9 January 2026
Language
FR
Document type
Thesis